

DATE

September 17, 2015

SECTORS

Healthcare

DEAL TYPE

M&A Advisory

DEAL LOCATIONS



DEAL TEAM



Joaquín Gonzalo Managing Director

DC Advisory advised The Riverside Company on the sale of Orliman to Magnum



Background

- Orliman is the leading Spanish manufacturer and distributor of non-invasive orthopedic devices. The company's products are used in the prevention of injury, treatment of chronic conditions and for recovery after surgery or injury
- Based in Valencia Spain, Orliman manufactures a broad portfolio of devices for the upper limb, torso and lower limb including both standard as well as made-to-measure products
- After investing in Orliman in 2010, Riverside expanded the company considerably through both organic growth and integration of add-on acquisition. These efforts helped to extend Orliman's leadership position in the Spanish market and accelerated the company's transformation into the leading player in Southern Europe
- Today, Orliman sells in more than 40 countries and 70% of sales are generated outside of Spain
- The Riverside Company is a global private equity firm focused on investing in and acquiring growing businesses valued at up to \$300 million. Since its founding in 1988, Riverside has invested in more than 400 transactions. The firm's international portfolio includes more than 80 companies

Process

DC Advisory were engaged by Riverside as exclusive financial advisors to conduct the

© DC Advisory 2022 dcadvisory.com



sale process of Orliman

- The process was launched following a market-testing exercise, with a small group of motivated, qualified bidders
- In parallel to the M&A sales process, DC Advisory contacted a handful of lending funds to provide indicative financing terms to private equity bidders
- Following a tailored international competitive process, Magnum Capital Industrial Partners agreed to acquire Orliman
- The sale represents a great exit for Riverside following the transformation of the Company from a family-owned business to a growing international enterprise during their hold period

© DC Advisory 2022 dcadvisory.com